These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9309192)

  • 1. Lymphocytes, cytokines, inflammation, and immune trafficking.
    Tsokos GC; Kovacs B; Liossis SN
    Curr Opin Rheumatol; 1997 Sep; 9(5):380-6. PubMed ID: 9309192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytes, cytokines, inflammation, and immune trafficking.
    Tsokos GC; Liossis SN
    Curr Opin Rheumatol; 1998 Sep; 10(5):417-25. PubMed ID: 9746856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytes, cytokines, inflammation, and immune trafficking.
    Tsokos GC
    Curr Opin Rheumatol; 1995 Sep; 7(5):376-83. PubMed ID: 8519609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocytes, cytokines, inflammation, and immune trafficking.
    Tsokos GC
    Curr Opin Rheumatol; 1996 Sep; 8(5):395-402. PubMed ID: 8941441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines play a central role in the pathogenesis of systemic lupus erythematosus.
    Singh AK
    Med Hypotheses; 1992 Dec; 39(4):356-9. PubMed ID: 1494323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
    Suzuki N; Ichino M; Mihara S; Kaneko S; Sakane T
    Arthritis Rheum; 1998 Feb; 41(2):344-53. PubMed ID: 9485093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune cell biochemical abnormalities in systemic lupus erythematosus.
    Liossis SN; Vassilopoulos D; Kovacs B; Tsokos GC
    Clin Exp Rheumatol; 1997; 15(6):677-84. PubMed ID: 9444427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential expression of B7.2 (CD86), but not B7.1 (CD80), on B cells induced by CD40/CD40L interaction is essential for anti-DNA autoantibody production in patients with systemic lupus erythematosus.
    Nagafuchi H; Shimoyama Y; Kashiwakura J; Takeno M; Sakane T; Suzuki N
    Clin Exp Rheumatol; 2003; 21(1):71-7. PubMed ID: 12673892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocytes, cytokines, inflammation, and immune trafficking.
    Tsokos GC
    Curr Opin Rheumatol; 1994 Sep; 6(5):461-7. PubMed ID: 7993702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand.
    Georgescu L; Vakkalanka RK; Elkon KB; Crow MK
    J Clin Invest; 1997 Nov; 100(10):2622-33. PubMed ID: 9366578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cell death and lupus].
    Fournié G
    Ann Med Interne (Paris); 1996; 147(7):472-9. PubMed ID: 9092357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Physiopathology of systemic lupus erythematosus: a 2014 update].
    Mathian A; Arnaud L; Amoura Z
    Rev Med Interne; 2014 Aug; 35(8):503-11. PubMed ID: 24262408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
    Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
    Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity.
    Miret C; Molina R; Filella X; García-Carrasco M; Claver G; Ingelmo M; Ballesta A; Font J
    Tumour Biol; 2003; 24(4):185-8. PubMed ID: 14654712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.
    Koshy M; Berger D; Crow MK
    J Clin Invest; 1996 Aug; 98(3):826-37. PubMed ID: 8698875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytokines and lupus].
    Emilie D; Llorente L; Galanaud P
    Ann Med Interne (Paris); 1996; 147(7):480-4. PubMed ID: 9092358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus.
    Gao N; Dresel J; Eckstein V; Gellert R; Störch H; Venigalla RK; Schwenger V; Max R; Blank N; Lorenz HM; Tretter T
    Arthritis Rheumatol; 2014 Oct; 66(10):2849-61. PubMed ID: 24942956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells.
    Yi Y; McNerney M; Datta SK
    J Immunol; 2000 Dec; 165(11):6627-34. PubMed ID: 11086108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus.
    Chu VT; Enghard P; Schürer S; Steinhauser G; Rudolph B; Riemekasten G; Berek C
    Arthritis Rheum; 2009 Jul; 60(7):2083-93. PubMed ID: 19565488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T- and B-cell abnormalities in systemic lupus.
    Cohen PL
    J Invest Dermatol; 1993 Jan; 100(1):69S-72S. PubMed ID: 8423400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.